Your browser doesn't support javascript.
2D MXenes with antiviral and immunomodulatory properties: A pilot study against SARS-CoV-2.
Unal, Mehmet Altay; Bayrakdar, Fatma; Fusco, Laura; Besbinar, Omur; Shuck, Christopher E; Yalcin, Süleyman; Erken, Mine Turktas; Ozkul, Aykut; Gurcan, Cansu; Panatli, Oguzhan; Summak, Gokce Yagmur; Gokce, Cemile; Orecchioni, Marco; Gazzi, Arianna; Vitale, Flavia; Somers, Julia; Demir, Emek; Yildiz, Serap Suzuk; Nazir, Hasan; Grivel, Jean-Charles; Bedognetti, Davide; Crisanti, Andrea; Akcali, Kamil Can; Gogotsi, Yury; Delogu, Lucia Gemma; Yilmazer, Açelya.
  • Unal MA; Stem Cell Institute, Ankara University, Balgat, Ankara, Turkey.
  • Bayrakdar F; Ministry of Health General Directorate of Public Health, Microbiology References Laboratory, Ankara, Turkey.
  • Fusco L; Department of Biomedical Sciences, University of Padua, Padua, Italy.
  • Besbinar O; Cancer Research Department, Sidra Medicine, Doha, Qatar.
  • Shuck CE; Stem Cell Institute, Ankara University, Balgat, Ankara, Turkey.
  • Yalcin S; Department of Biomedical Engineering, Ankara University, Golbasi, Ankara, Turkey.
  • Erken MT; A.J. Drexel Nanomaterials Institute and Department of Materials Science and Engineering, Drexel University, Philadelphia, PA, USA.
  • Ozkul A; Ministry of Health General Directorate of Public Health, Microbiology References Laboratory, Ankara, Turkey.
  • Gurcan C; Department of Biology, Gazi University, Ankara, Turkey.
  • Panatli O; Department of Virology, Faculty of Veterinary Medicine, Ankara University, Ankara, Turkey.
  • Summak GY; Biotechnology Institute, Ankara University, Ankara, Turkey.
  • Gokce C; Stem Cell Institute, Ankara University, Balgat, Ankara, Turkey.
  • Orecchioni M; Department of Biomedical Engineering, Ankara University, Golbasi, Ankara, Turkey.
  • Gazzi A; Department of Biomedical Engineering, Ankara University, Golbasi, Ankara, Turkey.
  • Vitale F; Stem Cell Institute, Ankara University, Balgat, Ankara, Turkey.
  • Somers J; Department of Biomedical Engineering, Ankara University, Golbasi, Ankara, Turkey.
  • Demir E; La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Yildiz SS; Department of Biomedical Sciences, University of Padua, Padua, Italy.
  • Nazir H; Department of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy.
  • Grivel JC; Department of Neurology, Bioengineering, Physical Medicine & Rehabilitation, Center for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
  • Bedognetti D; Oregon Health & Sciences University, Department of Molecular and Medical Genetics, Portland, OR, USA.
  • Crisanti A; Oregon Health & Sciences University, Department of Molecular and Medical Genetics, Portland, OR, USA.
  • Akcali KC; Ministry of Health General Directorate of Public Health, Microbiology References Laboratory, Ankara, Turkey.
  • Gogotsi Y; Department of Chemistry, Ankara University, Tandogan, Ankara, Turkey.
  • Delogu LG; Deep Phenotyping Core, Sidra Medicine, Doha, Qatar.
  • Yilmazer A; Cancer Research Department, Sidra Medicine, Doha, Qatar.
Nano Today ; 38: 101136, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1142162
ABSTRACT
Two-dimensional transition metal carbides/carbonitrides known as MXenes are rapidly growing as multimodal nanoplatforms in biomedicine. Here, taking SARS-CoV-2 as a model, we explored the antiviral properties and immune-profile of a large panel of four highly stable and well-characterized MXenes - Ti3C2Tx, Ta4C3T x , Mo2Ti2C3T x and Nb4C3T x . To start with antiviral assessment, we first selected and deeply analyzed four different SARS-CoV-2 genotypes, common in most countries and carrying the wild type or mutated spike protein. When inhibition of the viral infection was tested in vitro with four viral clades, Ti3C2T x in particular, was able to significantly reduce infection only in SARS-CoV-2/clade GR infected Vero E6 cells. This difference in the antiviral activity, among the four viral particles tested, highlights the importance of considering the viral genotypes and mutations while testing antiviral activity of potential drugs and nanomaterials. Among the other MXenes tested, Mo2Ti2C3T x also showed antiviral properties. Proteomic, functional annotation analysis and comparison to the already published SARS-CoV-2 protein interaction map revealed that MXene-treatment exerts specific inhibitory mechanisms. Envisaging future antiviral MXene-based drug nano-formulations and considering the central importance of the immune response to viral infections, the immune impact of MXenes was evaluated on human primary immune cells by flow cytometry and single-cell mass cytometry on 17 distinct immune subpopulations. Moreover, 40 secreted cytokines were analyzed by Luminex technology. MXene immune profiling revealed i) the excellent bio and immune compatibility of the material, as well as the ability of MXene ii) to inhibit monocytes and iii) to reduce the release of pro-inflammatory cytokines, suggesting an anti-inflammatory effect elicited by MXene. We here report a selection of MXenes and viral SARS-CoV-2 genotypes/mutations, a series of the computational, structural and molecular data depicting deeply the SARS-CoV-2 mechanism of inhibition, as well as high dimensional single-cell immune-MXene profiling. Taken together, our results provide a compendium of knowledge for new developments of MXene-based multi-functioning nanosystems as antivirals and immune-modulators.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Language: English Journal: Nano Today Year: 2021 Document Type: Article Affiliation country: J.nantod.2021.101136

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Language: English Journal: Nano Today Year: 2021 Document Type: Article Affiliation country: J.nantod.2021.101136